国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2010年
23期
2892-2895
,共4页
促红细胞生成素%慢性心衰%LVEF%再住院率
促紅細胞生成素%慢性心衰%LVEF%再住院率
촉홍세포생성소%만성심쇠%LVEF%재주원솔
Erythropoietin%Chronic heart failure%LVEF%Admission rates
目的 观察在慢性心衰标准治疗的基础上加用促红细胞生成素(EPO)皮下注射的临床疗效及预后.方法 选择60例慢性心衰患者,随机分为2组,对照组(常规治疗组)29例服用β受体阻滞剂+血管紧张素转化酶抑制剂(ACEI)或血管紧张素受体拮抗剂(ARB)+利尿剂,症状严重时加用强心药.治疗组31例在对照组的基础上皮下注射EPO 100 lU/kg,每周1次,疗程6个月.治疗前后采用超声心动图及血常规进行疗效观察;并统计两组治疗后症状改善率、再住院率、死亡率.结果 EPO治疗组与对照组比较,治疗后两组左室射血分数(LVEF)及血红蛋白(HB)浓度均有所提高,左室舒张末期内径(LVEDD)、左室收缩期末内径(LVESD)均有缩小,但EPO组明显,与对照组比较,有统计学差异;治疗后与治疗前比较,EPO组症状改善率、心衰再住院率、死亡率下降更明显,两组比较有统计学差异.结论 促红细胞生成素能改善慢性心衰患者的心功能、并使心衰住院率、死亡率进一步下降,长期使用安全有效,值得临床研究应用.
目的 觀察在慢性心衰標準治療的基礎上加用促紅細胞生成素(EPO)皮下註射的臨床療效及預後.方法 選擇60例慢性心衰患者,隨機分為2組,對照組(常規治療組)29例服用β受體阻滯劑+血管緊張素轉化酶抑製劑(ACEI)或血管緊張素受體拮抗劑(ARB)+利尿劑,癥狀嚴重時加用彊心藥.治療組31例在對照組的基礎上皮下註射EPO 100 lU/kg,每週1次,療程6箇月.治療前後採用超聲心動圖及血常規進行療效觀察;併統計兩組治療後癥狀改善率、再住院率、死亡率.結果 EPO治療組與對照組比較,治療後兩組左室射血分數(LVEF)及血紅蛋白(HB)濃度均有所提高,左室舒張末期內徑(LVEDD)、左室收縮期末內徑(LVESD)均有縮小,但EPO組明顯,與對照組比較,有統計學差異;治療後與治療前比較,EPO組癥狀改善率、心衰再住院率、死亡率下降更明顯,兩組比較有統計學差異.結論 促紅細胞生成素能改善慢性心衰患者的心功能、併使心衰住院率、死亡率進一步下降,長期使用安全有效,值得臨床研究應用.
목적 관찰재만성심쇠표준치료적기출상가용촉홍세포생성소(EPO)피하주사적림상료효급예후.방법 선택60례만성심쇠환자,수궤분위2조,대조조(상규치료조)29례복용β수체조체제+혈관긴장소전화매억제제(ACEI)혹혈관긴장소수체길항제(ARB)+이뇨제,증상엄중시가용강심약.치료조31례재대조조적기출상피하주사EPO 100 lU/kg,매주1차,료정6개월.치료전후채용초성심동도급혈상규진행료효관찰;병통계량조치료후증상개선솔、재주원솔、사망솔.결과 EPO치료조여대조조비교,치료후량조좌실사혈분수(LVEF)급혈홍단백(HB)농도균유소제고,좌실서장말기내경(LVEDD)、좌실수축기말내경(LVESD)균유축소,단EPO조명현,여대조조비교,유통계학차이;치료후여치료전비교,EPO조증상개선솔、심쇠재주원솔、사망솔하강경명현,량조비교유통계학차이.결론 촉홍세포생성소능개선만성심쇠환자적심공능、병사심쇠주원솔、사망솔진일보하강,장기사용안전유효,치득림상연구응용.
Objective To observe the clinical curative effect and prognosis of chronic heart failure standard therapy combined with erythropoietin (EPO) subcutaneous injection. Methods 60 patients with chronic heart failure were se lected, and randomly divided into the treatment group and the control group (conventional) 29 patients taking beta blockers + angiotensin 1-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (arbs) + diuretics, a serious symptoms of heart. 31 cases in treatment group were injected by 1001U/kg epithelial EPO, 1 time each week, treatment for six months. Echocardiography and routine blood were carried out for clinical observation before and after the treatment and mark the hospitalization period symptoms and mortality rates. Resulta After treatment, the left ventricular ejection fraction (LVEF) and hemoglobin (HB) concentrations were all improved, and left ventricular end-diastolic diameter (LVEDD) and left ventricular shrink diameter LVESD (final) were all narrow, but EPO group, compared with controls, showed significant difference on the symptoms period, mortality rates.Conclusion It shows thaterythropoietin can improve cardiac function in patients with chronic heart failure, and reduce the heart rate and mortality, and it's safe and effective for long-term use, clinical application research should be carried out.
